Pharmacogenomics and gemcitabine

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Rosell, R ^a,f   Cobo, M ^b   Isla, D ^c   Camps, C ^d   Massuti, B ^e  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

BRCA1; Cisplatin; ERCC1; Gemcitabine; Gucleotide excision repair; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BRCA1 PROTEIN; CISPLATIN; COMPLEMENTARY DNA; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GEFITINIB; GEMCITABINE; MESSENGER RNA; NAVELBINE; OXALIPLATIN; PACLITAXEL; PARAFFIN; PROTEIN TYROSINE KINASE INHIBITOR; RIBONUCLEOTIDE REDUCTASE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN METASTASIS; BREAST CANCER; BRONCHUS BIOPSY; CANCER INHIBITION; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DNA ADDUCT; DNA DAMAGE; EXCISION REPAIR; GENE MUTATION; HOMOLOGOUS RECOMBINATION; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; MUTATIONAL ANALYSIS; OBSERVATIONAL STUDY; OVARY CANCER; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DNA-BINDING PROTEINS; ENDONUCLEASES; GENES, BRCA1; HUMANS; LUNG NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 33745605221     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj942     Document Type: Article

References (32)

1. Boyle P, Ferlay J. Cancer incident and mortality in Europe, 2004. Ann Oncol 2005; 16: 481-488.
2. Sandler AB, Nemunaitis J, Denham C et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18: 122-130.
3. Smit EF, van Meerbeeck JPAM, Lianes P et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitbine in advanced non-small-cell lung cancer: A phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003; 21: 3909-3917.
4. Le Chevalier T, Scagliotti G, Natale R et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancers: A meta-analysis of survival outcomes. Lung Cancer 2005; 47: 69-80.
5. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells. Role of ERCC1-XPF. Biochem Pharmacol 2000; 60: 1305-1313.
6. Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients, Clin Cancer Res 2004; 10: 1318-1325.
7. Rosell R, Taron M, Camps C et al. Influence of genetic markers on survival in non-small cell lung cancer. Drugs of Today 2003; 39: 775-786.
8. Rosell R, Taron M, Barnadas A et al. Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003; 10: 297-305.
9. Rosell R, Taron M, Alberola V et al. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 2003; 41: S97-S102.
10. Zeng-Rong N, Paterson J, Alpert L et al. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res 1995; 55: 4760-4764.
11. Van de Vaart PJM, Belderbos J, De Jong D et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000; 89: 160-166.
12. Bosken C, Wei Q, Amos C et al. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002; 94: 1091-1099.
13. Ferry KV, Hamilton TC and Johnson SW. Increased nucleotide excision repair in cisplatin resistant ovarian cancer cells. Biochem Pharmacol 2000; 60: 1305-1313.
14. Dabholkar M, Vionnet J, Bostick-Bruton F et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94: 703-708.
15. Metzger R, Leichman CG, Danenberg K et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-316.
16. Shirota Y, Stoehlmacher J, Brabender J et al. ERCC1 and thymidylate synythase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-4304.
17. Lord RVN, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small-cell lung cancer. Clin Cancer Res 2002; 8: 2286-2291.
18. Rosell R, Cobo M, Isla D et al. ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC patients (p). J Clin Oncol 2005 ASCO Annual Meeting Proceedings (Abstr 7002): 621s.
19. Husain A, He G, Venkatraman ES et al. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum (II). Cancer Res 1998; 58: 1120-1123.
20. Quinn JE, Kennedy RD, Mullan PB et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63: 6221-6228.
21. Tassone P, Tagliaferri P, Perricelli A et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Brit J Cancer 2003; 88: 1285-1291.
22. Fedier A, Steiner RA, Schwarz VA et al. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol 2003; 22: 1169-1173.
23. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 1-6.
24. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
25. Taron M, Rosell R, Felip E et al. BRCA mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13: 2443-2449.
26. Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Cancer Res 2004; 10: 1318-1325.
27. Weber F, Fukino K, Sawada T et al. Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Brit J Cancer 2005; 92: 1992-1926.
28. Tokumo M, Toyooka S, Kiura K et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small-cell lung cancers. Clin Cancer Res 2005; 11: 1167-1173.
29. Mitsudomi T, Kosaka T, Endoh H et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-2520.
30. Chou TY, Chiu C-H, Li L-H et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small-cell lung cancer. Clin Cancer Res 2005; 11: 3750-3757.
31. Taron M, Ichinose Y, Rosell R et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 2005 (in press).
32. Cortes-Funes H, Gomez C, Rosell R et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol 2005; 16: 1081-1086.